Old drugs sometimes find new uses, and that’s the case with pan beta blockers’ potential to boost immunotherapy treatments and extend the lives of patients with a potentially lethal form of skin cancer — melanoma — that has spread.
In a study published in January in OncoImmunology, the Penn State College of Medicine in Hershey, Pa., reviewed data on 195 patients, with 67 percent of those using pan beta blockers estimated to be alive five years after starting immunotherapy, as compared with only 25 percent of those taking a different beta blocker (beta 1) or no beta blockers.
Study results were further confirmed by Penn State’s complementary mouse study, which showed biological justification for how pan beta blockers improve the effectiveness of immunotherapy drugs, which is a treatment that activates your body’s own immune system against cancer.
“Several studies were showing that cancer patients on beta blockers had improved prognoses, including some with melanoma, and there’s a lot of evidence in breast cancers, where most of the work was done,” said Todd D. Schell, a College of Medicine professor of microbiology and immunology and study leader.
But few clinical studies to date have focused on the impacts of specific beta blockers on melanoma or other cancers.
So the Penn State retrospective study used existing data about patients, including outcomes from cancer treatments and other drugs being used, to reveal specific outcomes associated with particular beta blockers.
The study holds particular importance for those with melanoma that has spread to other parts of the body, which has a 15 percent to 20 percent survival rate beyond five years.
“What we found was a statistically significant increase in overall survival for those taking pan beta blockers compared to the other two groups,” including those taking no beta blockers or using beta 1 selective blockers, a more popular blood-pressure medication nowadays. Even though the number of patients using beta blockers in the study was relatively small, researchers said they are optimistic about the results.
Melanoma is a cancer of the specialized cells in the skin that produce melanin — the pigment that protects the skin by causing cells to darken when exposed to ultraviolet rays. Cancer occurs when skin layers fail to repair damage to melanin-producing cells known as melanocytes.
Skin type and genetics can be additional factors in promoting the cancer. Melanoma typically spreads to the brain, bones, liver and lungs, research shows.
The study focus was beta nerve-cell receptors found in muscle, artery and organ cells, among others, that function as part of the sympathetic nervous system to produce the “fight-or-flight” response in stressful situations. More specifically, physiological stress occurs when adrenaline (epinephrine and/or norepinephrine) is released from nerve endings and binds to a cell’s specialized receptors.
Nowadays beta 1 blockers are the preferable blood-pressure treatment that focus on receptors in heart tissue. Blocking stress signaling to the tissue reduces heart rate and blood pressure. While pan beta blockers also bind to heart tissue and lower blood pressure, they also bind and reduce stress signaling in multiple cell types, Dr. Schell said.
Because cells of the immune system also express beta [nerve-cell] receptors, cellular stress can adversely affect the immune response against cancer, potentially causing immunotherapy drugs to be less effective in treating metastasized melanoma, Dr. Schell said.
“There was some evidence in scientific literature that shows that if you block these receptors with beta blockers you can improve immune responsiveness and slow cancer progression,” he said.
The study concludes that “pan beta blocker usage may improve clinical outcomes for patients who receive multiple types of immunotherapy in the setting of metastatic melanoma.”
For now, the study provides insufficient medical foundation for doctors to prescribe pan beta blockers to those undergoing immunotherapy for metastasized melanoma. It does, however, “provide enough evidence to move forward for a prospective study” to test the impact under more controlled conditions.
“It’s probably too early” to advocate that such patients use pan beta blockers, even though they have a long safety record in medical literature,” Dr. Schell said. “A clinical trial needs to be done to confirm the results.”
Joseph Baar, director of clinical breast cancer research at the Seidman Cancer Center of University Hospitals Cleveland Medical Center, agreed that the next step must be a randomized clinical trial involving one group of melanoma patients who receive pan beta blockage and another that doesn’t. He was not involved in the Penn State study.
“Clinical outcomes are then compared to determine if a real difference exists between the two groups,” Dr. Baar said, noting that the Penn State study shows the “potential beneficial effect of pan beta blockade in patients receiving immunotherapy for metastatic melanoma.”
David Templeton; dtempleton@post-gazette.com or 412-263-1578. Twitter: @templetoons.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.